Covid-19 and Vaccine Equity: Does a patent waiver matter?

Please use this identifier to cite or link to this item: https://ir.iimcal.ac.in:8443/jspui/handle/123456789/4716

Full metadata record

DC Field	Value	Language
dc.contributor.author	Unni, V.K.	-
dc.contributor.author	Forbes India	-
dc.date.accessioned	2024-03-06T11:21:43Z	-
dc.date.available	2024-03-06T11:21:43Z	-
dc.date.issued	2021-05-20	-
dc.identifier.uri	https://www.forbesindia.com/article/iim-calcutta/covid19-and-vaccine-equity-does-a-patent-waiver-matter/68039/1#:~:text=The%20answer%20is%20no.,shortage%20and%20inadequate%20production%20facilities	-
dc.identifier.uri	https://ir.iimcal.ac.in:8443/jspui/handle/123456789/4716	-
dc.description	Source: News: Online: Forbes India Dated: 20-05-2021	en_US
dc.description.abstract	While a patent waiver may be good news in the long-term, it may not translate into any meaningful gains for India, professor of public policy and management group, IIM Calcutta writes, adding vaccine equity may be an elusive dream	en_US
dc.language.iso	en_US	en_US
dc.publisher	Forbes India	en_US
dc.subject	Covid-19	en_US
dc.subject	Trade Related Aspects of Intellectual Property Rights	en_US
dc.subject	TRIPS	en_US
dc.subject	Intellectual Property	en_US
dc.subject	Covishield	en_US
dc.subject	Sputnik V	en_US
dc.subject	mRNA	en_US
dc.title	Covid-19 and Vaccine Equity: Does a patent waiver matter?	en_US
dc.type	Article	en_US
Appears in Collections:	IIMC Stakeholders

Files in This Item:

File	Description	Size	Format
ppm-11.pdf	Covid-19 and Vaccine Equity: Does a patent waiver matter?	367.18 kB	Adobe PDF	View/Open